• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

仅通过活检治疗的乳腺低级别导管原位癌诊断后15至25年,癌灶持续局部复发。

Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.

作者信息

Page D L, Dupont W D, Rogers L W, Jensen R A, Schuyler P A

机构信息

Vanderbilt University School of Medicine, Department of Pathology, Nashville, Tennessee, USA.

出版信息

Cancer. 1995 Oct 1;76(7):1197-200. doi: 10.1002/1097-0142(19951001)76:7<1197::aid-cncr2820760715>3.0.co;2-0.

DOI:10.1002/1097-0142(19951001)76:7<1197::aid-cncr2820760715>3.0.co;2-0
PMID:8630897
Abstract

BACKGROUND

The stratification of ductal carcinoma in situ (DCIS) of the human breast into prognostically relevant categories by size and histologic pattern is a current concern. Few studies have been able to follow women after the identification of any type of DCIS when they have had biopsy only.

METHODS

This is an extension of a follow-up study of a group of 28 women with small, noncomedo ductal carcinomas in situ that were excised by biopsy only, published in 1982. All these women have now been successfully followed for an average of almost 30 years.

RESULTS

The overall risk of development of invasive carcinoma for these women over almost 30 years is nine times that of the general population (95% confidence interval, 4.7-17). This is similar to the 11-fold elevation in relative risk that was determined after about 15 years of follow-up. All invasive carcinomas have developed in the same area in the same breast. There were two women in whom invasive carcinoma developed between 20 and 30 years after initial biopsy. One other woman had an extensive noncomedo DCIS that was identified 25 years after her initial biopsy, but had no evidence of invasive disease.

CONCLUSIONS

The natural history of small, noncomedo DCIS can last over at least 2 decades, with invasive carcinoma developing at the same site in which DCIS was previously discovered in a significant percentage of women (broadly, between 25%-50%). This is quite different from the natural history of comedo DCIS or any type of DCIS treated purposefully by surgery alone.

摘要

背景

依据大小和组织学模式将人类乳腺导管原位癌(DCIS)分层为具有预后相关性的类别是当前关注的问题。仅有少数研究能够在仅进行活检确诊任何类型DCIS的女性中进行随访。

方法

这是一项对一组28例仅通过活检切除的小的、非粉刺型导管原位癌女性进行随访研究的扩展,该研究于1982年发表。现在所有这些女性均已成功随访平均近30年。

结果

这些女性在近30年中发生浸润性癌的总体风险是普通人群的9倍(95%置信区间,4.7 - 17)。这与随访约15年后确定的相对风险升高11倍相似。所有浸润性癌均在同一乳腺的相同区域发生。有两名女性在初次活检后20至30年之间发生浸润性癌。另一名女性在初次活检25年后发现广泛的非粉刺型DCIS,但无浸润性疾病证据。

结论

小的、非粉刺型DCIS的自然病程至少可持续20年以上,在相当比例的女性(大致在25% - 50%之间)中,浸润性癌在先前发现DCIS的同一部位发生。这与粉刺型DCIS或仅通过手术进行针对性治疗的任何类型DCIS的自然病程有很大不同。

相似文献

1
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.仅通过活检治疗的乳腺低级别导管原位癌诊断后15至25年,癌灶持续局部复发。
Cancer. 1995 Oct 1;76(7):1197-200. doi: 10.1002/1097-0142(19951001)76:7<1197::aid-cncr2820760715>3.0.co;2-0.
2
The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.仅接受活检治疗的女性乳腺导管原位癌的自然病史在超过30年的长期随访中得以揭示。
Cancer. 2005 Jun 15;103(12):2481-4. doi: 10.1002/cncr.21069.
3
Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS).乳腺钼靶检测到的导管原位癌(DCIS)的保守手术及放疗结果。
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):949-57. doi: 10.1016/s0360-3016(97)00153-3.
4
Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.保乳手术治疗导管原位癌女性的长期随访:年龄的影响
Cancer. 1999 Nov 1;86(9):1757-67. doi: 10.1002/(sici)1097-0142(19991101)86:9<1757::aid-cncr18>3.0.co;2-v.
5
Pathologic features of initial biopsy specimens associated with residual intraductal carcinoma on reexcision in patients with ductal carcinoma in situ of the breast referred for breast-conserving therapy.接受保乳治疗的乳腺导管原位癌患者初次活检标本的病理特征与再次切除时残留导管内癌的相关性。
Am J Surg Pathol. 1999 Nov;23(11):1340-8. doi: 10.1097/00000478-199911000-00004.
6
Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.微浸润性乳腺癌:单机构经验的临床病理分析
Cancer. 2000 Mar 15;88(6):1403-9.
7
Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy.经保守手术及放射治疗的乳腺钼靶检测导管原位癌局部复发的结局及预后因素
Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):791-7. doi: 10.1016/0360-3016(94)00486-2.
8
Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy.接受保乳治疗的乳腺钼靶检测原位导管癌患者局部复发的相关因素。
Cancer. 2000 Feb 1;88(3):596-607. doi: 10.1002/(sici)1097-0142(20000201)88:3<596::aid-cncr16>3.0.co;2-n.
9
Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization.乳腺非浸润性导管癌:组织学分类的相关性。
Hum Pathol. 1993 Jan;24(1):16-23. doi: 10.1016/0046-8177(93)90057-n.
10
Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.导管原位癌治疗后局部复发的预测因素:一项荟萃分析。
Cancer. 1999 Feb 1;85(3):616-28.

引用本文的文献

1
Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers.导管原位癌术前试验中的招募障碍:一项针对高危女性、幸存者及医疗服务提供者的探索性定性研究
Breast Cancer Res Treat. 2025 Jul 3. doi: 10.1007/s10549-025-07742-2.
2
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events.一项多机构登记研究的见解表明,导管原位癌内分泌治疗的持续时间会影响二次事件。
NPJ Breast Cancer. 2025 Jul 1;11(1):63. doi: 10.1038/s41523-025-00774-3.
3
Expression of T cell-related proteins in breast ductal carcinoma .
T细胞相关蛋白在乳腺导管癌中的表达
Histol Histopathol. 2025 Apr;40(4):467-475. doi: 10.14670/HH-18-805. Epub 2024 Sep 2.
4
Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.导管原位癌内分泌治疗的持续时间对二次事件有影响:来自两个学术医学中心的大量病例队列的见解。
Res Sq. 2024 Jan 11:rs.3.rs-3403438. doi: 10.21203/rs.3.rs-3403438/v1.
5
Predicting Underestimation of Invasive Cancer in Patients with Core-Needle-Biopsy-Diagnosed Ductal Carcinoma In Situ Using Deep Learning Algorithms.利用深度学习算法预测核心针活检诊断为导管原位癌患者的浸润性癌低估。
Tomography. 2022 Dec 20;9(1):1-11. doi: 10.3390/tomography9010001.
6
Prediction of the histologic upgrade of ductal carcinoma using a combined radiomics and machine learning approach based on breast dynamic contrast-enhanced magnetic resonance imaging.基于乳腺动态对比增强磁共振成像,采用联合放射组学和机器学习方法预测导管癌的组织学升级。
Front Oncol. 2022 Nov 2;12:1032809. doi: 10.3389/fonc.2022.1032809. eCollection 2022.
7
De-Escalating the Management of In Situ and Invasive Breast Cancer.降低原位和浸润性乳腺癌的管理强度
Cancers (Basel). 2022 Sep 20;14(19):4545. doi: 10.3390/cancers14194545.
8
MiRNA expression deregulation correlates with the Oncotype DX DCIS score.miRNA 表达失调与 Oncotype DX DCIS 评分相关。
Breast Cancer Res. 2022 Sep 12;24(1):62. doi: 10.1186/s13058-022-01558-4.
9
Ductal Carcinoma in Situ: State-of-the-Art Review.导管原位癌:最新综述。
Radiology. 2022 Feb;302(2):246-255. doi: 10.1148/radiol.211839. Epub 2021 Dec 21.
10
A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast.钙剂和维生素 D 补充剂与乳腺导管原位癌风险的随机试验。
JNCI Cancer Spectr. 2021 Aug 31;5(4). doi: 10.1093/jncics/pkab072. eCollection 2021 Aug.